Home|Journals|Articles by Year|Audio Abstracts


Egypt. J. Exp. Biol. (Zoo.). 2014; 10(1): 41-46


Mohamed L. Salem Shaimaa Talat Ahmed El-Barbary.


Anticancer chemotherapy is a successful treatment of tumor to kill or to low the multiplying rate of tumor cells. Although the immunomodulatory effect of single chemotherapy has been investigated, the effects of combinatorial chemotherapy are ill defined. Therefore the aim of this study was to evaluate effects of CTX and CIS alone or in combination as conventional chemotherapeutic drugs on the total and differential numbers of leukocytes. Groups of adult female Swiss albino (CD1) mice were treated with intraperitoneal (i.p.) injection of 0.5 x 106 cells/mouse of Ehrlichs ascites carcinoma (EAC) cells. After one day of injection, mice were i.p. treated either with PBS, (10 µg/mouse) CIS, (4 mg/mouse) CTX or in combination with different sequential treatment protocol, mice were bled on day11 and complete blood count (CBC) was assessed. Treatment with low dose of (10 µg/mouse) CIS or with high dose of (4 mg/mouse) CTX followed by (10 µg/mouse) CIS induced slight decreases in the total numbers of white blood cells (WBCs) and absolute numbers of neutrophils and lymphocytes. Treatment with high dose (4 mg/mouse) of CTX or with low dose of (10 µg/mouse) CIS followed by CTX (4mg/mouse) induced marked decreases in the total numbers of WBCs, relative and absolute numbers of neutrophils and lymphocytes. The data suggested that certain sequential treatment protocol of high dose of chemotherapy can induce lower lymphopenia, which have important implications in cancer treatment.

Key words: Chemotherapy, Cyclophosphamide, Cisplatin, Ehrlich carcinoma, White blood cells, lymphocytes, neutrophils

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.